Current and historical daily PE Ratio for Extrawell Pharmaceutical Holdings Ltd (
HKSE:00858
) from 1999 to Jun 19 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Extrawell Pharmaceutical stock (HKSE:00858) PE ratio as of Jun 19 2024 is 0.
More Details
Extrawell Pharmaceutical Holdings Ltd (HKSE:00858) PE Ratio (TTM) Chart
Extrawell Pharmaceutical Holdings Ltd (HKSE:00858) PE Ratio (TTM) Historical Data
View and export this data going back to 1999. Start your Free Trial
Total 1164
- 1
- 2
- 3
- 4
- 5
- 6
- 13
| Extrawell Pharmaceutical PE Ratio (TTM) Historical Data | |||
|---|---|---|---|
| Date | PE Ratio (TTM) Data | Date | PE Ratio (TTM) Data |
| 2024-06-20 | At Loss | 2024-04-12 | At Loss |
| 2024-06-18 | At Loss | 2024-04-11 | At Loss |
| 2024-06-17 | At Loss | 2024-04-10 | At Loss |
| 2024-06-14 | At Loss | 2024-04-09 | At Loss |
| 2024-06-13 | At Loss | 2024-04-08 | At Loss |
| 2024-06-12 | At Loss | 2024-04-05 | At Loss |
| 2024-06-11 | At Loss | 2024-04-03 | At Loss |
| 2024-06-07 | At Loss | 2024-04-02 | At Loss |
| 2024-06-06 | At Loss | 2024-03-28 | At Loss |
| 2024-06-05 | At Loss | 2024-03-27 | At Loss |
| 2024-06-04 | At Loss | 2024-03-26 | At Loss |
| 2024-06-03 | At Loss | 2024-03-25 | At Loss |
| 2024-05-31 | At Loss | 2024-03-22 | At Loss |
| 2024-05-30 | At Loss | 2024-03-21 | At Loss |
| 2024-05-29 | At Loss | 2024-03-20 | At Loss |
| 2024-05-28 | At Loss | 2024-03-19 | At Loss |
| 2024-05-27 | At Loss | 2024-03-18 | At Loss |
| 2024-05-24 | At Loss | 2024-03-15 | At Loss |
| 2024-05-23 | At Loss | 2024-03-14 | At Loss |
| 2024-05-22 | At Loss | 2024-03-13 | At Loss |
| 2024-05-21 | At Loss | 2024-03-12 | At Loss |
| 2024-05-20 | At Loss | 2024-03-11 | At Loss |
| 2024-05-17 | At Loss | 2024-03-08 | At Loss |
| 2024-05-16 | At Loss | 2024-03-07 | At Loss |
| 2024-05-14 | At Loss | 2024-03-06 | At Loss |
| 2024-05-13 | At Loss | 2024-03-05 | At Loss |
| 2024-05-10 | At Loss | 2024-03-04 | At Loss |
| 2024-05-09 | At Loss | 2024-03-01 | At Loss |
| 2024-05-08 | At Loss | 2024-02-29 | At Loss |
| 2024-05-07 | At Loss | 2024-02-28 | At Loss |
| 2024-05-06 | At Loss | 2024-02-27 | At Loss |
| 2024-05-03 | At Loss | 2024-02-26 | At Loss |
| 2024-05-02 | At Loss | 2024-02-23 | At Loss |
| 2024-04-30 | At Loss | 2024-02-22 | At Loss |
| 2024-04-29 | At Loss | 2024-02-21 | At Loss |
| 2024-04-26 | At Loss | 2024-02-20 | At Loss |
| 2024-04-25 | At Loss | 2024-02-19 | At Loss |
| 2024-04-24 | At Loss | 2024-02-16 | At Loss |
| 2024-04-23 | At Loss | 2024-02-15 | At Loss |
| 2024-04-22 | At Loss | 2024-02-14 | At Loss |
| 2024-04-19 | At Loss | 2024-02-09 | At Loss |
| 2024-04-18 | At Loss | 2024-02-08 | At Loss |
| 2024-04-17 | At Loss | 2024-02-07 | At Loss |
| 2024-04-16 | At Loss | 2024-02-06 | At Loss |
| 2024-04-15 | At Loss | 2024-02-05 | At Loss |
Extrawell Pharmaceutical Holdings Ltd (HKSE:00858) PE Ratio (TTM) Comparison
| Company | Market Cap(Mil) | PE Ratio (TTM) |
|---|
Business Description
Business Description
Extrawell Pharmaceutical Holdings Ltd
NAICS : 325412
ISIN : BMG3285Q1134
Compare
Compare
Traded in other countries / regions
00858.Hong Kong IPO Date
1999-10-03Description
Extrawell Pharmaceutical Holdings Ltd is an investment holding company. The company's operating segment includes Manufacturing; Trading and Gene Development. It generates maximum revenue from the Manufacturing segment. The manufacturing segment is engaged in the development, manufacture, and sales of pharmaceutical products. Its trading segment is engaged in the marketing and distribution of imported pharmaceutical products. The gene development segment is engaged in the commercial exploitation and development of genome-related technology. Geographically, it derives a majority of its revenue from China.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers